Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: A new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Wilcox, Teresa K ^a   Chen, Wen Hung ^a   Howard, Kellee A ^a   Wiklund, Ingela ^a   Brooks, Jean ^b   Watkins, Michael L ^c   Cates, Charlotte E ^a   Tabberer, Maggie M ^b   Crim, Courtney ^c  

^a EVIDERA   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Chronic obstructive pulmonary disease; Dyspnea; Patient reported outcome measure; Shortness of breath; Shortness of breath with daily activities questionnaire

Indexed keywords

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY QUESTIONNAIRE; CONTENT VALIDITY; CONVERGENT VALIDITY; DAILY LIFE ACTIVITY; DYSPNEA; ELECTRONIC MEDICAL RECORD; FEMALE; GENDER BIAS; HUMAN; INSTRUMENT VALIDATION; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSYCHOMETRY; QUESTIONNAIRE; SELF REPORT; SHORTNESS OF BREATH WITH DAILY ACTIVITIES QUESTIONNAIRE; ST. GEORGE RESPIRATORY QUESTIONNAIRE; STRUCTURED INTERVIEW; UNITED STATES;

AGED; DYSPNEA; FACTOR ANALYSIS, STATISTICAL; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; PSYCHOMETRICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; UNITED STATES;

EID: 84887360950     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-196     Document Type: Article

References (28)

1. GOLD Global Strategy for the Diagnosis, Management, and Prevention of COPD 2011, http://www.goldcopd.org, GOLD.
2. Ho SF, OMahony MS, Steward JA, Breay P, Buchalter M, Burr ML. Dyspnoea and quality of life in older people at home. Age Ageing 2001, 30:155-159. 10.1093/ageing/30.2.155, 11395346.
3. Jolley CJ, Moxham J. A physiological model of patient-reported breathlessness during daily activities in COPD. Eur Respir Rev 2009, 18:66-79. 10.1183/09059180.00000809, 20956127.
4. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J 2009, 33:262-272.
5. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients. Chest 2002, 121:1434-1440. 10.1378/chest.121.5.1434, 12006425.
6. Aaron SD, Vandemheen KL, Clinch JJ, Ahuja J, Brison RJ, Dickinson G, Hébert PC. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 2002, 121:688-696. 10.1378/chest.121.3.688, 11888946.
7. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J, Dickinson G, Brison R, Rowe BH, Dreyer J, Yetisir E, Cass D, Wells G. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003, 348:2618-2625. 10.1056/NEJMoa023161, 12826636.
8. Parker CM, Voduc N, Aaron SD, Webb KA, ODonnell DE. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005, 26:420-428. 10.1183/09031936.05.00136304, 16135722.
9. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991, 85(Suppl B):25-31.
10. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St George's Respiratory Questionnaire. Ann Rev Respir Dis 1992, 145:1321-1327.
11. Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. CHEST 2007, 132:456-463. 10.1378/chest.06-0702, 17646240.
12. Howard K, Berry P, Petrillo J, Wiklund I, Roberts L, Watkins M, Crim C, Wilcox T. Development of the shortness of breath with daily activities questionnaire (SOBDA). Value Health 2012, 15:1042-1050. 10.1016/j.jval.2012.06.018, 23244806.
13. Food and Drug Administration Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims 2009, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf, Food and Drug Administration.
14. Schilling RSF, Hughes JPW, Dingwall-Fordyce I. Disagreement between observers in an epidemiological study of respiratory disease. Br Med J 1955, 1:65-68. 10.1136/bmj.1.4905.65, 2060801, 13219343.
15. American Thoracic Society Statement Guidelines for the six-minute walk test 2002, http://www.thoracic.org/statements/resources/pfet/sixminute.pdf, American Thoracic Society Statement.
16. Borg G. Ratings of perceived exertion and heart rates during short-term cycle exercise and their use in a new cycling strength test. Int J Sports Med 1982, 3:153-158. 10.1055/s-2008-1026080, 7129724.
17. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982, 14:377-381.
18. Muthén LK, Muthén B. Mplus User's Guide 1998-2004, Los Angeles: Muthén & Muthén, 3.
19. Andrich D. Controversy and the Rasch model: a characteristic of incompatible paradigms?. Med Care 2004, 42:I7-I16.
20. Rasch Unidimensional Measurement Models (RUMM) 2020 RUMM Laboratory Pty Ltd 2004, Rasch Unidimensional Measurement Models (RUMM) 2020.
21. Hays RD, Revicki D, Coyne KS. Application of structural equation modeling to health outcomes research. Eval Health Prof 2005, 28:295-309. 10.1177/0163278705278277, 16123259.
22. Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998, 12:363-369. 10.1183/09031936.98.12020363, 9727786.
23. Crisafulli E, Clini EM. Measures of dyspnea in pulmonary rehabilitation. Multidiscip Respir Med 2010, 5:202-210. 10.1186/2049-6958-5-3-202, 3463047, 22958431.
24. European Medicines Agency Reflection paper on ethical and GCP aspects of clinical trials of medicinal products for human use conducted outside of the EU/EEA and submitted in marketing authorisation applications to the EU Regulatory Authorities 2012, http://www.emea.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125437.pdf, European Medicines Agency.
25. Jones PW. Health status and the spiral of decline. COPD 2009, 6:59-63. 10.1080/15412550802587943, 19229709.
26. Watkins ML, Wilcox TK, Tabberer M, Brooks JM, Donohue JF, Anzueto A, Chen W-H, Crim C. Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open 2013, 3(10):e003048. 3808824, 24154513.
27. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002, 77:371-383. 10.4065/77.4.371, 11936935.
28. Food and Drug Administration Draft guidance for industry chronic obstructive pulmonary disease: developing drugs for treatment 2007, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071575.pdf, Food and Drug Administration.